Patents
Sitemap › C07 - Organic chemistry › C07D - Heterocyclic compounds › C07D 413 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
Patents for C07D 413 - Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms (64,687)
11/2010
11/25/2010US20100298388 Substituted benamidines as antibacterial agents
11/25/2010US20100298384 Novel oxazolidinone compounds as antiinfective agents
11/25/2010US20100298366 Chemokine receptor binding compounds
11/25/2010US20100298346 Nitrogenous heterocyclic compounds with insecticidal activity, and the preparation and use thereof
11/25/2010US20100298328 1-Heterocyclylamino-2-Hydroxy-3-Amino-Omega-Arylalkanes
11/25/2010US20100298327 Aprepitant polymorph mixtures
11/25/2010US20100298326 Carboxamide compounds and their use as calpain inhibitors
11/25/2010US20100298325 Pyridine derivatives for the treatment of amyloid-related diseases
11/25/2010US20100298324 Prolyl Hydroxylase Inhibitors
11/25/2010US20100298323 Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
11/25/2010US20100298322 Quinazolines and Related Heterocyclic Compounds, and Their Therapeutic Use
11/25/2010US20100298321 Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
11/25/2010US20100298316 Benzothiazoles Having Histamine H3 Receptor Activity
11/25/2010US20100298315 Novel 6-triazolopyridazinesulfanyl benzothiazole and benzimidazole derivatives, method for production thereof and application as medicaments and pharmnaceutical compositions and novel use as met inhibitors
11/25/2010US20100298312 Substituted pyrimidinyl-amines as protein kinase inhibitors
11/25/2010US20100298310 Thiazole Derivatives as Kinase Inhibitors
11/25/2010US20100298303 Cgrp receptor antagonists
11/25/2010US20100298302 Novel protein kinase modulators
11/25/2010US20100298301 Oxazole tyrosine kinase inhibitors
11/25/2010US20100298299 non-peptide derivatives as bradykinin b1 antagonists
11/25/2010US20100298297 Tetrahydropyridothienopyrimidine Compounds and Methods of Use Thereof
11/25/2010US20100298295 2-biphenylamino-4-aminopyrimidine derivatives as kinase inhibitors
11/25/2010US20100298293 Substituted oxazolidinones and their use
11/25/2010US20100298291 Fused bicyclic-substituted amines as histamine-3 receptor ligands
11/25/2010US20100298290 Benzoxazepines as Inhibitors of PI3K/mTOR and Methods of Their Use and Manufacture
11/25/2010US20100298288 Cetp inhibitors derived from benzoxazole arylamides
11/25/2010US20100298285 Biclycloheteroaryl Compounds as P2x7 Modulators and Uses Thereof
11/25/2010US20100298284 Benzamides and related inhibitors of factor xa
11/25/2010US20100298278 Inhibitors of beta-secretase for the treatment of alzheimer's disease
11/25/2010US20100298270 Novel Compounds and Methods of Using Them
11/25/2010US20100297097 Compounds
11/25/2010CA2763099A1 Benzoxazepines based p13k/mt0r inhibitors against proliferative diseases
11/25/2010CA2762527A1 Isoxazolines as inhibitors of fatty acid amide hydrolase
11/25/2010CA2760766A1 Novel pyrimidine derivatives and their use in the treatment of cancer and further diseases
11/24/2010EP2253630A1 Heterocyclic compound and use thereof
11/24/2010EP2253625A1 Pyridazinones, the preparation and the use thereof
11/24/2010EP2253620A1 Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
11/24/2010EP2253614A1 Inhibitors of IAP
11/24/2010EP2253328A1 Cycloalkyl inhibitors of potassium channel function
11/24/2010EP2253327A1 Pharmaceutical composition containing a compound having angiotensin II antagonistic activity in combination with another compound
11/24/2010EP2252610A1 Substituted piperidines as renin inhibitors
11/24/2010EP2252609A1 Pyridin-2-yl derivatives as immunomodulating agents
11/24/2010EP2252606A1 Pyrimidylmethyl sulfonamide compounds
11/24/2010EP2252600A1 Substituted triazinylmethyl sulfonamides
11/24/2010EP2252594A2 5-fluoro pyrimidine derivatives as fungicides
11/24/2010EP2252372A1 2-aminoquinolines
11/24/2010EP2252299A1 Fused pyridone m1 receptor positive allosteric modulators
11/24/2010EP2029586B1 Isoindolin-1-one-, isoindolin-3-one- and isoindolin-1,3-dione-derivatives and use thereof
11/24/2010EP1899330B1 Substituted glycinamides having an antithrombotic and factor xa-inhibiting effect
11/24/2010EP1501829B1 Thiadiazoles or oxadiazoles and their use as inhibitors of jak protein kinase
11/24/2010EP1497287B1 Quinoline derivatives in combination with 5-FU or CPT-11 for use in the treatment of cancer
11/24/2010EP1497285B1 Benzoxazinone-derived compounds, their preparation und use as medicaments
11/24/2010EP1364946B1 Isoxazoline derivative and herbicide comprising the same as active ingredient
11/24/2010CN1925859B 4-(sulfanyl-pyrimidin-4-ylmethyl)-morpholine derivatives and related compounds as GABA receptor ligands for the treatment of anxiety, depression and epilepsy
11/24/2010CN1889922B Use of osteopontin in dental formulations
11/24/2010CN1578660B Lactam-containing compounds and derivatives thereof as factor xa inhibitors
11/24/2010CN101896482A Novel thiophene derivatives as S1P1/EDG1 agonist
11/24/2010CN101896472A HEDGEHOG pathway antagonists and therapeutic applications thereof
11/24/2010CN101896465A Cannabinoid receptor modulators
11/24/2010CN101896461A Gamma secretase modulators
11/24/2010CN101891736A 1,3,4-thiadiazole (oxadiazole) derivatives based on benzoisoselenothiazolidone structure, and preparation and application thereof
11/24/2010CN101891735A Biphenyl sulfafurazole compound, synthesis method and application thereof
11/24/2010CN101891680A Modulators of atp-binding cassette transporters
11/24/2010CN101891678A 4-(N,N-dimethyl) aminopyridine derivate and synthesis method thereof
11/24/2010CN101175722B Azetidine derivatives as ccr-3 receptor antagonists
11/23/2010US7838682 Glucagon-like peptide-1 receptor agonists, the preparation and the use of the same
11/23/2010US7838530 Antiproliferative agent in the prevention or treatment of tumors which are sensitive to inhibition of EGF and erbB receptor tyrosine kinases;1-({4-[(3-chloro-2-fluorophenyl)amino]-7-methoxyquinazolin-6-yl}methyl)-L-prolinamide
11/23/2010US7838527 Methods of treating cancer and related methods
11/23/2010US7838525 modulators of glucose metabolism, GPCR, RUP3; metabolic disorders and complications thereof such as diabetes and obesity; 4-[5-Cyano-6-(6-methylsulfanyl-pyridin-3-ylamino)-pyrimidin-4-yloxy]-piperidine-1-carboxylic acid tert-butyl ester
11/23/2010US7838524 Substituted pyrazolyl urea derivatives useful in the treatment of cancer
11/23/2010US7838522 with polyglycolized glyceride (macrogol glyceride); Gelucires"; multiple sclerosis, asthma, scleroderma, endometriosis; 1,3-benzothiazol-2(3H)-ylidene{2-[(1,4-dimethylpiperazin-2-yl)methoxy]pyrimidin-4-yl}acetonitrile; adding to melt as powder under stirring resulting in homogeneous molten dispersion
11/23/2010US7838521 phosphodiesterase PDE4 inhibitor; preparing claimed 3-(dialkoxy)phenyl-4-aminopyran intermediate from the claimed 4-oxo compound starting with hydrobromination of the corresponding phenylacetylene; antiinflammatory for airways and skin; respiratory; bronchodilator
11/23/2010US7838518 1-(4-methoxynaphthalene-1-sulfonyl)-2,3-dihydro-1H-indole-3-carboxylic acid [2-(1-methyl-pyrrolidin-2-yl)-ethyl]amide; selective affinity for 5-HT6 receptor; psychosis, schizophrenia, depression, neurological disorders, cognitive enhancement, Parkinson's disease, ALS, Alzheimer's, Huntington's disease
11/23/2010US7837981 Methods for imaging soluble A-beta
11/23/2010CA2496295C Novels pyrazole compounds as transforming growth factor (tgf) inhibitors
11/23/2010CA2487489C Mitotic kinesin inhibitors
11/23/2010CA2480776C Methods of preparation of the 2-(7-chloro-1,8-naphthyridine-2yl)-3-(5-methyl-2-oxo-hexyl)-1-isoindolinone
11/23/2010CA2434775C Compounds for use in the treatment of skin conditions
11/23/2010CA2377309C Compounds for the modulation of ppar.gamma. activity
11/18/2010WO2010132601A1 Antiviral compounds
11/18/2010WO2010132599A1 Compounds with two fused bicyclic heteroaryl moieties as modulators of leukotriene a4 hydrolase
11/18/2010WO2010131738A1 Azetidine compound and medicinal use thereof
11/18/2010WO2010131147A1 Cyclobutenedione derivatives
11/18/2010WO2010130945A1 7-aza-spiro[3.5]nonane-7-carboxylate derivatives, preparation thereof, and therapeutic use thereof
11/18/2010WO2010130944A1 Cyclopenta[c]pyrrole-2-carboxylate derivatives, preparation thereof, and therapeutic use thereof
11/18/2010WO2010130943A1 5-membered heterocyclic compound cyclopenta[c]pyrrolylalkylcarbamate derivatives, preparation thereof, and therapeutic use thereof
11/18/2010WO2010130794A1 5-pyridin-3-yl-1,3-dihydro-indol-2-on derivatives and their use as modulators of aldosterone synthase and/or cyp11b1
11/18/2010WO2010130773A2 Benzoxazolone derivatives as aldosterone symthase inhibitors
11/18/2010WO2010130034A1 Inhibitors of human immunodeficiency virus replication
11/18/2010WO2010117323A8 Isoxazol-3(2h)-one analogs as therapeutic agents
11/18/2010WO2010111626A3 Poly (adp-ribose) polymerase (parp) inhibitors
11/18/2010WO2010110685A8 Pyrimidinyl and 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy
11/18/2010WO2010104193A3 Intermediate compound for synthesizing pharmaceutical agent and production method thereof
11/18/2010WO2010059611A3 Inhibitors of diacylglycerol acyltransferase
11/18/2010WO2010036613A8 Novel cyclic benzimidazole derivatives useful anti-diabetic agents
11/18/2010WO2010034838A3 Antiproliferative compounds
11/18/2010WO2010033543A3 Substituted benzamides as cannabinoid receptor ligands
11/18/2010WO2010033168A3 Modulators of p2x3 receptor activity
11/18/2010US20100292282 Synthesis and crystalline forms of cb-1 antagonist/inverse agonist
11/18/2010US20100292274 Haloalkyl heteroaryl benzamide compounds
1 ... 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 ... 647